[go: up one dir, main page]

WO2017208174A3 - Methods of treating disease with pfkfb3 inhibitors - Google Patents

Methods of treating disease with pfkfb3 inhibitors Download PDF

Info

Publication number
WO2017208174A3
WO2017208174A3 PCT/IB2017/053209 IB2017053209W WO2017208174A3 WO 2017208174 A3 WO2017208174 A3 WO 2017208174A3 IB 2017053209 W IB2017053209 W IB 2017053209W WO 2017208174 A3 WO2017208174 A3 WO 2017208174A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
subject
pfkfb3
administering
treating disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2017/053209
Other languages
French (fr)
Other versions
WO2017208174A2 (en
Inventor
Slavica TUDZAROVA-TRAJKOVSKA
Peter C. Butler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2017208174A2 publication Critical patent/WO2017208174A2/en
Publication of WO2017208174A3 publication Critical patent/WO2017208174A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The disclosure relates to methods for treating a protein misfolding disease in a subject comprising administering a 6-phosphofructo-2- kinase/fructose-2,6-biphosphatase 3 (PFKFB3) inhibitor to the subject. Further aspects relate to a method for treating or preventing protein misfolding-induced cell death in a cell, the method comprising administering a PFKFB3 inhibitor to the cell. The disclosure also describes methods for inhibiting or reducing beta-cell death in a subject with Type 2 diabetes, the method comprising administering a PFKFB3 inhibitor to the subject.
PCT/IB2017/053209 2016-05-31 2017-05-31 Methods of treating disease with pfkfb3 inhibitors Ceased WO2017208174A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662343377P 2016-05-31 2016-05-31
US62/343,377 2016-05-31

Publications (2)

Publication Number Publication Date
WO2017208174A2 WO2017208174A2 (en) 2017-12-07
WO2017208174A3 true WO2017208174A3 (en) 2018-02-01

Family

ID=60479205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/053209 Ceased WO2017208174A2 (en) 2016-05-31 2017-05-31 Methods of treating disease with pfkfb3 inhibitors

Country Status (1)

Country Link
WO (1) WO2017208174A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021007101A2 (en) * 2018-10-15 2021-07-27 Gero Discovery Limited Liability Company compound, compound for use as a neuroprotectant, pharmaceutically acceptable acid addition salt, derivative, n-oxide, solvate, tautomer, stereoisomer, racemate, physiologically acceptable salt, pharmaceutical composition, neuroprotective and antiaging pharmaceutical compositions, tangible medium, deletion agent, decrease, binding, inhibition or degradation of pfkfb3, pfkfb3, pfkfb3 inhibitors for use in neuroprotection, small molecule pfkfb3 kinase activity, pfkfb3 small molecule kinase activity, and small molecule pfkfb3 kinase activity pfkfb3 kinase, kits for treating a condition mediated by pfkfb3 and/or pfkfb4, a cancer, for antiaging treatment and for neuroprotection, immunosuppression methods and for treating a cancer, solid tumor, hematologic cancer, a bone cancer, osteosarcoma, disease, cerebral ischemia, neonatal ischemic stroke, neurological insult, ischemic stroke, accelerated aging of a cancer survivor, accelerated aging of an individual suffering from hiv, of a traumatic brain injury, of a human individual after an acute central nervous system injury, for the treatment of a disorder associated with the modulation of f-2 levels, 6-p2 in a mammal, for the treatment or prevention of an age-related disorder or disease or other antiaging treatment and for the prevention or treatment of consequences of chemotherapy and radiotherapy, for the treatment or prophylaxis of a disease or condition in which the inhibition of glycolysis has a beneficial effect, of neurodegenerative disease or condition in which the inhibition of glycolysis has a beneficial effect and of neurodegenerative disease or neurodegenerative condition, to intensify the effect of radiation cancer treatment, the radiation treatment effect of bone cancer and the effect of radiation treatment of osteosarcoma, to reduce the ability of cancer cells to repair their DNA and to reduce atherosclerotic inflammation and/or at least one of its clinical consequences, to sensitize the cancer cell to cytostatic and/or radiation therapy, and, methods for neuroprotection, to manufacture a medication, to manufacture a neuroprotective medication, to increase cell antioxidant capacity, to reduce glycolytic uptake in the neuron, to prevent apoptotic neuron death, to reduce glycolytic uptake in the astrocyte, to reactive inhibition of astrocyte proliferation, to protect a neuron against excitotoxicity, to protect of an enteric neuron against excitotoxicity, for attenuation or prevention of neuronal damage in a human individual, for prevention or treatment of age-related disease, for parameter improvement, for rejuvenation, for radioprotection, for change of biomarker or biomarkers of mortality, for the change of biomarker or biomarkers of longevity or
CN116096891A (en) * 2020-07-10 2023-05-09 雀巢产品有限公司 Nutritional compositions comprising MIR-3184
JP2023538612A (en) * 2020-08-18 2023-09-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Methods and compositions for diabetes treatment and beta cell regeneration
JP2024518003A (en) * 2021-05-16 2024-04-23 メタノイア バイオ インコーポレイテッド Methods and Compositions for Treating Cardiovascular Disease - Patent application
US20240269124A1 (en) * 2021-05-16 2024-08-15 Metanoia Bio Inc. Methods and compositions for treating neurological conditions
US20250074989A1 (en) * 2021-05-16 2025-03-06 Metanoia Bio Inc. Methods and compositions for treating pancreatic disease
CN115851793A (en) * 2022-09-23 2023-03-28 龙岩学院 Eukaryotic expression vector for efficiently expressing pig PFKFB3 gene and construction method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074884A1 (en) * 2007-06-18 2009-03-19 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074884A1 (en) * 2007-06-18 2009-03-19 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
LUOTO ET AL.: "Tumor hypoxia as a driving force in genetic instability", GENOME INTEGR., vol. 4, no. 1, 2013, pages 5, XP021166963 *
MUKHERJEE ET AL.: "Type 2 diabetes as a protein misfolding disease", TRENDS MOL MED., vol. 21, no. 7, 2015, pages 439 - 49, XP055459655 *
SALABEI ET AL.: "Type 2 Diabetes Dysregulates Glucose Metabolism in Cardiac Progenitor Cells", J BIOL CHEM., vol. 291, no. 26, 2016, pages 13634 - 48, XP055459653 *
WANG ET AL.: "Protein misfolding in the endoplasmic reticulum as a conduit to human disease", NATURE, vol. 529, no. 7586, January 2016 (2016-01-01), pages 326 - 35, XP055459666 *
WU ET AL.: "From acute ER stress to physiological roles of the Unfolded Protein Response", CELL DEATH DIFFER., vol. 13, no. 3, March 2006 (2006-03-01), pages 374 - 84, XP055459659 *
YADAV ET AL.: "Endoplasmic Reticulum Stress and Cancer", J CANCER PREV., vol. 19, no. 2, 2014, pages 75 - 88, XP055459647 *

Also Published As

Publication number Publication date
WO2017208174A2 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
WO2017208174A3 (en) Methods of treating disease with pfkfb3 inhibitors
PH12020551205A1 (en) Fap inhibitors
PH12015502310A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2018010374A (en) Inhibitors of wdr5 protein-protein binding.
PH12018502507B1 (en) Pyrazolopyrimidine derivatives as kinase inhibitor
HK1245677A1 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
EA201791576A1 (en) JAK INHIBITOR
WO2012064897A3 (en) Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use
BR112016015236A8 (en) compound, pharmaceutical composition, use of a compound, method of inhibition and method for treating or alleviating the severity of a disease.
WO2014031928A3 (en) Heterocyclic modulators of hif activity for treatment of disease
WO2015077540A3 (en) Compositions and methods for treating pulmonary hypertension
JOP20180094A1 (en) Heterocyclic compound as a protein kinase inhibito
WO2017019540A3 (en) Inhibitors of n-linked glycosylation and methods using same
WO2012125981A3 (en) Raf kinase inhibitors
BR112018071467A2 (en) method of treatment or prevention of liver disorders
WO2014186450A3 (en) Highly potent inhibitors of porcupine
WO2016004404A3 (en) Gls1 inhibitors for treating disease
WO2013169631A3 (en) Wnt protein signalling inhibitors
EA201692038A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION
AU2018258588A8 (en) Inhibitors of TRIM33 and methods of use
HK1246685A1 (en) Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
MY193996A (en) Tripeptide compound, preparation method therefor, and application thereof
NZ727715A (en) Novel heterocyclic compounds having prs enzyme inhibitory effect
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17805989

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17805989

Country of ref document: EP

Kind code of ref document: A2